Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Proteo, Inc. (OTC: PTEO).

Full DD Report for PTEO

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-07N/A0.08N/AN/A0
2018-12-06N/A0.08N/AN/A0
2018-12-05N/A0.08N/AN/A0
2018-12-04N/A0.08N/AN/A0
2018-12-03N/A0.08N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-09-144,0004,000100.0000Short
2018-09-071,4001,400100.0000Short
2018-09-0524,450136,95017.8532Cover
2018-02-088,80018,80046.8085Short
2018-01-031,5501,550100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on PTEO.


About Proteo, Inc. (OTC: PTEO)

Logo for Proteo, Inc. (OTC: PTEO)

Proteo Inc. with its wholly owned subsidiary Proteo Biotech AG, a German corporation, is a clinical stage drug development company focused on the development of anti inflammatory treatments for rare diseases with significant unmet needs. Proteo s lead product Elafin is a copy of a naturally occurring human anti inflammatory protein and promises an excellent therapeutic risk benefit profile. It is a potent inactivator of tissue destroying neutrophil elastase and proteinase , and was well tolerated in three randomized, double blinded, placebo controlled clinical studies. Elafin s ability to block tissue destroying proteases makes it a promising drug candidate for the prevention and treatment of tissue damage occurring in the course of major surgery, pulmonary diseases and severe reperfusion injury in organ transplantation. Elafin is under clinical development for prophylactic treatment of acute postoperative complications, with focus on the prevention of postoperative inflammatory complications in the surgical therapy of esophageal cancer. It s potential for the treatment of pulmonary arterial hypertension and lung diseases is currently evaluated in preclinical models. Elafin has obtained orphan drug designations for the treatment of complications of esophageal cancer surgery as well as for the treatment of pulmonary arterial hypertension in the United States and the European Union. Proteo intends to establish international strategic partnerships for the development, manufacturing and marketing of Elafin.

 

Contact Information

 

 

Current Management

  • Birge Bargmann / President, CEO, CFO
  • Oliver Wiedow / Chairman
  • Birge Bargmann /
  • Hartmut Weigelt /

Current Share Structure

  • Market Cap: $1,193,968 - 03/16/2018
  • Authorized: 300,000,000 - 03/15/2018
  • Issue and Outstanding: 23,879,350 - 03/15/2018
  • Float: 11,053,350 - 06/29/2015

 


Recent Filings from (OTC: PTEO)

Notification that form 10-Q will be submitted late
Filing Type: NT 10-QFiling Source: edgar
Filing Date: May, 15 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 27 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 02 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: November, 07 2017

 

 


Daily Technical Chart for (OTC: PTEO)

Daily Technical Chart for (OTC: PTEO)


Stay tuned for daily updates and more on (OTC: PTEO)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: PTEO)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in PTEO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of PTEO and does not buy, sell, or trade any shares of PTEO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/